

Serial No.: 09/635,521

-2-

Group Art Unit:1636

Please add new claims 70-78 as follows:

- Added by Amendment A*
70. The method of claim 25, wherein the cardiovascular disorder is selected from the group consisting of ischemia reperfusion injury, restenosis, arterial inflammation, vascular wall remodeling, ventricular remodeling, rapid ventricular pacing, coronary microembolism, tachycardia, bradycardia, vascular heart disease, atrial fibrillation, long-QT syndrome, congestive heart failure, angina, heart failure, hypertension, myocardial infarction, coronary artery disease, aneurysm, cavernous angioma, tricuspid atresia, and truncus arteriosus.
71. The method of claim 25, wherein the cardiovascular disorder is an endothelial cell disorder.
72. The method of claim 71, wherein the endothelial cell disorder is selected from the group consisting of tumorigenesis, tumor metastasis, psoriasis, diabetic retinopathy, endometriosis, Grave's disease, ischemic disease, and chronic inflammatory diseases.
73. The method of claim 73, wherein the tumorigenic disease is selected from the group consisting of carcinoma, sarcoma, lymphoma and leukemia.
74. The method of claim 25, wherein the ability of the compound to modulate the activity of the GPCR 4941 polypeptide is determined by using a cell-based assay.
75. The method of claim 74, wherein the cell-based assay monitors intracellular calcium, cyclic AMP or diacylglycerol levels.
76. The method of claim 25, wherein the ability of the compound to modulate the activity of the GPCR 4941 polypeptide is determined by direct binding of a compound to GPCR 4941.
77. The method of claim 25, wherein the ability of the compound to modulate the activity of the GPCR 4941 polypeptide is determined by detecting the induction of a reporter gene.